Journal of Clinical Oncology, Vol 13, 2342-2353, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Bone marrow-sparing and prevention of alopecia by AS101 in non-small- cell lung cancer patients treated with carboplatin and etoposide

B Sredni, M Albeck, T Tichler, A Shani, J Shapira, I Bruderman, R Catane, B Kaufman and Y Kalechman
Cancer, AIDS and Immunology Research Institute, Marilyn Finkler Cancer Research Center, Bar Ilan University, Ramat Gan, Israel.

PURPOSE: The aim of this study was to evaluate the ability of the immunomodulator AS101 to prevent chemotherapy-induced neutropenia and thrombocytopenia and thus allow patients to receive full-dose antineoplastic agents according to protocol design. We also aimed to determine the production level of various hematopoietic growth factors in treated patients. PATIENTS AND METHODS: This study of 44 unresectable or metastatic non-small-cell lung cancer (NSCLC) patients was an open-label prospective randomized study of standard chemotherapy alone versus chemotherapy plus AS101. Each patient received carboplatin (300 mg/m2 intravenously [IV] on day 1 of a 28-day cycle, and etoposide (VP-16) (200 mg/m2 orally) on days 3, 5, and 7 of each cycle. AS101 was administered at 3 mg/m2 three times per week starting 2 weeks before chemotherapy. RESULTS: AS101, which manifested no major toxicity, significantly reduced neutropenia and thrombocytopenia and thus allowed all treated patients to receive full-dose antineoplastic agents, in contrast to only 28.5% of the control group. Continuous treatment with AS101 significantly reduced the number of days per patient of thrombocytopenia and neutropenia and did not provide protection to tumor cells as reflected by the higher overall response rate compared with the chemotherapy-alone arm. Interestingly, AS101 treatment also significantly prevented chemotherapy-induced alopecia. These effects correlate with the ability of AS101-treated patients to increase significantly the production of colony-stimulating factors (CSFs) interleukin-1 alpha (IL-1 alpha) and IL-6. CONCLUSION: AS101 has significant bone marrow (BM)-sparing effects and prevents hair loss in chemotherapy-treated patients, with minimal overall toxicity. These effects are probably due to increased production of IL-1 alpha, IL-6, and granulocyte-macrophage (GM)-CSF.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Carmely, D. Meirow, A. Peretz, M. Albeck, B. Bartoov, and B. Sredni Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice Hum. Reprod., June 1, 2009; 24(6): 1322 - 1329. [Abstract] [Full Text] [PDF]

				B. Sredni, R. Geffen-Aricha, W. Duan, M. Albeck, F. Shalit, H. M. Lander, N. Kinor, O. Sagi, A. Albeck, S. Yosef, et al. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models FASEB J, June 1, 2007; 21(8): 1870 - 1883. [Abstract] [Full Text] [PDF]

				I. Sinuani, Z. Averbukh, I. Gitelman, M. J. Rapoport, J. Sandbank, M. Albeck, B. Sredni, and J. Weissgarten Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10-induced TGF-beta secretion: effect of the immunomodulator AS101 on this process Am J Physiol Renal Physiol, August 1, 2006; 291(2): F384 - F394. [Abstract] [Full Text] [PDF]

				Y. Kalechman, U. Gafter, T. Weinstein, A. Chagnac, I. Freidkin, A. Tobar, M. Albeck, and B. Sredni Inhibition of Interleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis: ASSOCIATION WITH DEPHOSPHORYLATION OF STAT3 J. Biol. Chem., June 4, 2004; 279(23): 24724 - 24732. [Abstract] [Full Text] [PDF]

				B. Sredni, M. Weil, G. Khomenok, I. Lebenthal, S. Teitz, Y. Mardor, Z. Ram, A. Orenstein, A. Kershenovich, S. Michowiz, et al. Ammonium Trichloro(dioxoethylene-o,o')tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop Cancer Res., March 1, 2004; 64(5): 1843 - 1852. [Abstract] [Full Text] [PDF]

				Y. Kalechman, B. Sredni, T. Weinstein, I. Freidkin, A. Tobar, M. Albeck, and U. Gafter Production of the Novel Mesangial Autocrine Growth Factors GDNF and IL-10 Is Regulated by the Immunomodulator AS101 J. Am. Soc. Nephrol., March 1, 2003; 14(3): 620 - 630. [Abstract] [Full Text] [PDF]

				Y. Kalechman, U. Gafter, R. Gal, G. Rushkin, D. Yan, M. Albeck, and B. Sredni Anti-IL-10 Therapeutic Strategy Using the Immunomodulator AS101 in Protecting Mice from Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention J. Immunol., July 1, 2002; 169(1): 384 - 392. [Abstract] [Full Text] [PDF]

				Y. Kalechman, G. Strassmann, M. Albeck, and B. Sredni Up-Regulation by Ammonium Trichloro(Dioxoethylene-0,0') Tellurate (AS101) of Fas/Apo-1 Expression on B16 Melanoma Cells: Implications for the Antitumor Effects of AS101 J. Immunol., October 1, 1998; 161(7): 3536 - 3542. [Abstract] [Full Text] [PDF]

				D. S. Alberts and R. T. Dorr New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors Oncologist, February 1, 1998; 3(1): 15 - 34. [Abstract] [Full Text]